Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jan 1;110(1):228-233.
doi: 10.3324/haematol.2024.285768.

Comparing the clinical trial efficacy versus real-world effectiveness of treatments for multiple myeloma: a population-based study

Alissa Visram  1 , Kelvin Kar-Wing Chan  2 , Hsien Seow  3 , Gregory Pond  3 , Anastasia Gayowsky  4 , Ghulam Rehman Mohyuddin  5 , Arleigh McCurdy  6 , Irwindeep Sandhu  7 , Christopher Venner  8 , Guido Lancman  9 , Amaris Balitsky  3 , Tom Kouroukis  3 , Robert Bruins  10 , Shaji Kumar  11 , Rafael Fonseca  12 , Hira Mian  3
Affiliations

Comparing the clinical trial efficacy versus real-world effectiveness of treatments for multiple myeloma: a population-based study

Alissa Visram et al. Haematologica. .
No abstract available

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Meta-analysis of the progression-free survival and overall survival in the real-world and randomized clinical trial cohorts. (A) summarizes the progression-free survival (PFS) and (B) overall survival (OS) in real-world (RW) versus randomized clinical (RCT) patient cohorts with multiple myeloma (MM), stratified by regimens used in the newly diagnosed MM (NDMM) versus relapsed refractory MM (RRMM) treatment setting. Rd: lenalidomide and dexamethasone; VRd: bortezomib, lenalidomide and dexamethasone; Kd: carfilzomib and dexamethasone; KRd: carfilzomib and Rd; DVd: daratumumab, bortezomib and dexamethasone; DRd: daratumumab and Rd; Pd: pomalidomide and dexamethasone; CI: confidence interval.
See this image and copyright information in PMC

References

    1. Facon T, Dimopoulos MA, Dispenzieri A, et al. . Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma. Blood. 2018;131(3):301-310. - PMC - PubMed
    1. Durie BGM, Hoering A, Sexton R, et al. . Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT). Blood Cancer J. 2020;10(5):53. - PMC - PubMed
    1. Dimopoulos MA, Moreau P, Palumbo A, et al. . Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. Lancet Oncol. 2016;17(1):27-38. - PubMed
    1. Stewart AK, Rajkumar SV, Dimopoulos MA, et al. . Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med. 2015;372(2):142-152. - PubMed
    1. Mateos MV, Sonneveld P, Hungria V, et al. . Daratumumab, bortezomib, and dexamethasone versus bortezomib and dexamethasone in patients with previously treated multiple myeloma: three-year follow-up of CASTOR. Clin Lymphoma Myeloma Leuk. 2020;20(8):509-518. - PubMed

LinkOut - more resources